WaveMan
WaveMan · Company
MGTX · Meiragtx Holdings Plc
> Search tickers & screens ⌘K
LIVE
← All companies

MGTX MeiraGTx (MGTX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001735438
Quote by TradingView
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
117
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · no price filed

What the filings say about MGTX

Insiders, 180 days
-$3.4M net sold
3 sellers · 29% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.7M
3 notices

MeiraGTx insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, MeiraGTx Holdings plc insiders sold a net $3.4M of stock across 35 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Giroux Richard
CFO & COO
SELL
2026-10-20 SEC
56,000
$557.2K
-6.9%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Jul 21, 2026.
  • The trade is 6.6% of the 852,530 shares held after it.
  • 1 other insider sold within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO & COO Giroux Richard sold about $557.2K of MGTX under a 10b5-1 plan on Oct 20, 2026; 1 other insider sold within 30 days and 117 funds added in the latest 13F quarter.
Naylor Stuart
CHIEF SCI OFCR, OPHTHALMOLOGY
SELL
2026-10-06 SEC
27,659
$294.3K
-15.2%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jul 7, 2026.
  • The trade is 4.5% of the 613,187 shares held after it.
  • 1 other insider sold within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF SCI OFCR, OPHTHALMOLOGY Naylor Stuart sold about $294.3K of MGTX under a 10b5-1 plan on Oct 6, 2026; 1 other insider sold within 30 days and 117 funds added in the latest 13F quarter.
Forbes Alexandria
PRESIDENT & CEO
SELL
2026-08-18 SEC
62,000
$859.3K
-38.7%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on May 19, 2026.
  • The trade is 4.7% of the 1,325,695 shares held after it.
  • 1 other insider sold within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT & CEO Forbes Alexandria sold about $859.3K of MGTX on Aug 18, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 117 funds added in the latest 13F quarter.
Giroux Richard
CFO & COO
SELL
2026-07-21 SEC
56,000
$700.6K
-24.5%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Apr 21, 2026.
  • The trade is 6.2% of the 908,530 shares held after it.
  • 2 other insiders sold within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO & COO Giroux Richard sold about $700.6K of MGTX on Jul 21, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 117 funds added in the latest 13F quarter.
Naylor Stuart
CHIEF SCI OFCR, OPHTHALMOLOGY
SELL
2026-07-07 SEC
2,547
$35.3K
-35.1%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Apr 7, 2026.
  • The trade is 0.4% of the 665,958 shares held after it.
  • 1 other insider sold within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF SCI OFCR, OPHTHALMOLOGY Naylor Stuart sold about $35.3K of MGTX on Jul 7, 2026; 1 other insider sold within 30 days and 117 funds added in the latest 13F quarter.
35 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 30 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$3.4M over 180 days
-$1.7M over 90 days
below 75% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
117 funds bought in last quarter
more than 75% of Pharma & Biotech
Revenue
+144.6% year over year
more than 87% of Pharma & Biotech
Margin
-140.3% net margin
below 61% of Pharma & Biotech
Buybacks
$18.2M repurchased, FY to 2026-06-30
below 61% of Pharma & Biotech
Short interest
11.1% of the float short (float per yahoo 2026-10-26) · 5.0 days to cover · settled 2026-09-30
more than 57% of Pharma & Biotech
What changed in the last 30 days
Oct 20CFO & COO Giroux Richard sold $557.2K under a 10b5-1 plan (Oct 20)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 20Officer Richard Giroux filed to sell $557.2K by Oct 20 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 6Officer Naylor Stuart filed to sell $294.3K by Oct 6 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 6CHIEF SCI OFCR, OPHTHALMOLOGY Naylor Stuart sold $294.3K under a 10b5-1 plan (Oct 6)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.

Watch MGTX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+4.9%12M
-20%+10%+41%+71%2025-102025-122026-022026-042026-062026-082026-10 2026-08-18 · Forbes Alexandria sold $859.3K2026-07-21 · Giroux Richard sold $700.6K2026-04-21 · Giroux Richard sold $572.3K2026-05-19 · Forbes Alexandria sold $568.5K2026-10-20 · Giroux Richard sold $557.2K2026-03-24 · Forbes Alexandria sold $459.4K2026-07-07 · Naylor Stuart sold $374.2K2026-10-06 · Naylor Stuart sold $294.3K2026-04-07 · Naylor Stuart sold $258.9K2026-07-07 · Naylor Stuart sold $35.3K2026-10-20 · Richard Giroux filed to sell $557.2K2026-10-06 · Naylor Stuart filed to sell $294.3K2026-08-18 · Alexandria Forbes filed to sell $859.3K2026-07-21 · Richard Giroux filed to sell $700.6K2026-07-07 · Naylor Stuart filed to sell $368.7K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MGTX: institutional holders (13F)

13F holdings, latest reported quarter
Sanofi
12,197,737 sh
$164.8M
PERCEPTIVE ADVISORS LLC
10,786,658 sh
$145.7M
Rubric Capital Management LP
9,100,000 sh
$122.9M
JOHNSON & JOHNSON
6,641,064 sh
$89.7M
BlackRock, Inc.
4,757,178 sh
$64.3M

Congress trades in MGTX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MGTX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Richard Giroux
Filed 2026-10-20
$557.2K
Naylor Stuart
Filed 2026-10-06
$294.3K
Alexandria Forbes
Filed 2026-08-18
$859.3K
Richard Giroux
Filed 2026-07-21
$700.6K
Naylor Stuart
Filed 2026-07-07
$368.7K

MGTX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
AlphaCentric Life Sciences and Healthcare Fund
$735.9K position · as of 2026-06-30
1.6%
NORTH SQUARE KENNEDY MICROCAP FUND
$208.9K position · as of 2026-05-31
0.6%
Invesco NASDAQ Future Gen 200 ETF
$108.2K position · as of 2026-05-31
0.6%
Nuveen Quant Small Cap Equity Fund
$6.2M position · as of 2026-07-31
0.2%
Nuveen Quant Mid Cap Growth Fund
$848.6K position · as of 2026-07-31
0.1%
Eventide Small Cap ETF
$44.6K position · as of 2026-07-31
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$8.3M
$11.8M
$4.9M
+21%
n/a
2024
$6.9M
$6.1M
$4.4M
-7%
n/a
2023
$6.3M
$5.8M
$3.7M
+8%
n/a
2022
$7.7M
-$1.1M
$5.3M
-73%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $3.4M sold by insiders over 180 days, 117 funds added last quarter, $1.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

MGTX financials

Revenue growth
+144.6%
XBRL, annual
Net margin
-140.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$397.5M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+19.9%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$10.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term debt only, 2023-03-31 (39 months older than the period end); equity 2026-06-30
Cash flow to debt
65.81x
TTM operating cash flow over long-term debt only, 2023-03-31 (39 months older than the period end)
Return on equity
+72.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+26.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
+76.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
12.93x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$738.7M
market value at close 2026-10-26 on 2026-08-11 shares, plus long-term debt only, 2023-03-31 (39 months older than the period end), minus cash 2026-06-30
FCF yield
+1.2%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$81.4M$33.3M$14.0M$15.9M
Operating income-$106.0M-$164.2M-$137.1M-$116.4M
Net income-$114.2M-$147.8M-$84.0M-$129.6M
EPS (diluted)-1.42-2.12-1.49-2.87
Operating cash flow-$46.4M-$104.5M-$105.4M-$73.1M
Cash$65.9M$103.7M$129.6M$115.5M
Long-term debtn/an/an/a$262.0K
SEC XBRL, fiscal years, as known on 2026-10-28

MGTX Stock Sonar score 6/7 axes

Find similar shapesCompare

MGTX ranks highest on profitability (96th percentile) and financial health (92nd), and lowest on insider conviction (13th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
96
Inputs
  • Return on equity+72.2% · 96 pct, sector of 545
  • Return on assets+26.5% · 94 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed+76.1% · 99 pct, sector of 576
Financial health
92
Inputs
  • Debt to equity0.00x · 85 pct, sector of 352
  • Cash flow to debt65.81x · 99 pct, sector of 371
Growth
87
Inputs
  • Revenue growth, YoY+144.6% · 87 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
13
Inputs
  • Net Form 4 buying (codes P and S), 180d-$2.5M · 26 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
75
Inputs
  • Funds adding, latest quarter117 · 75 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
54
Inputs
  • Short interest, % of float+11.1% · 36 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+6.9% · 72 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

MGTX filings, in plain words

Are MeiraGTx insiders buying or selling MGTX?

In the 180 days to 2026-10-28, MeiraGTx insiders were net sellers, a net $3.4M across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of MGTX?

Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.7M of stock; the latest, by Richard Giroux, was filed 2026-10-20.

Read the full summary

In the 180 days to 2026-10-28, MeiraGTx insiders were net sellers of MGTX, a net $3.4M across purchases and sales reported on Form 4 by 3 sellers. 29% of the 7 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies